Research programme: neurodegenerative disorders therapeutics - NsGene

Drug Profile

Research programme: neurodegenerative disorders therapeutics - NsGene

Alternative Names: BrainRepair research project - NsGene; EC biodelivery programme - NsGene; ECB-PD; ECT-PD; Meteorin; Meteorin-like growth factors - NsGene; Ns G34; NsG 0301; NsG 33

Latest Information Update: 16 Dec 2016

Price : $50

At a glance

  • Originator NsGene
  • Developer AlzeCure; NsGene; Sanofi Genzyme
  • Class Antibodies; Nerve growth factors
  • Mechanism of Action Glial cell line-derived neurotrophic factor modulators; Neuron stimulants; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Corticobasal degeneration; Motor neuron disease; Neurodegenerative disorders; Neuropathic pain; Parkinson's disease

Most Recent Events

  • 08 Jan 2016 NsGene and Takeda agree to co-develop recombinant glial cell line-derived neurotrophic factor (GDNF) for Parkinson's disease
  • 21 Nov 2013 Preclinical trials in Corticobasal degeneration in Sweden (Intracerebral)
  • 21 Nov 2013 Preclinical trials in Corticobasal degeneration in USA (Intracerebral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top